GIAPREZA
Total Payments
$3.9M
Transactions
11,921
Doctors
6,320
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $349,779 | 1,829 | 1,398 |
| 2023 | $220,182 | 1,374 | 1,042 |
| 2022 | $366,094 | 1,399 | 965 |
| 2021 | $791,620 | 1,028 | 656 |
| 2020 | $136,249 | 819 | 588 |
| 2019 | $560,663 | 2,039 | 1,081 |
| 2018 | $1.4M | 3,433 | 2,027 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.2M | 350 | 29.9% |
| Honoraria | $1.0M | 392 | 26.4% |
| Unspecified | $737,257 | 46 | 19.1% |
| Food and Beverage | $497,330 | 10,220 | 12.9% |
| Consulting Fee | $191,711 | 73 | 5.0% |
| Travel and Lodging | $141,153 | 583 | 3.6% |
| Space rental or facility fees (teaching hospital only) | $68,480 | 57 | 1.8% |
| Education | $33,163 | 198 | 0.9% |
| Grant | $20,000 | 2 | 0.5% |
Payments by Type
General
$3.1M
11,875 transactions
Research
$737,257
46 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Multi-Center, Randomized, Open-Label, Parallel Group Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Adult Patients With Transfusion-Dependent Beta Thalassemia | La Jolla Pharmaceutical Company | $419,361 | 0 |
| A STUDY OF LJPC-501 IN PEDIATRIC PATIENTS WITH HYPOTENSION | La Jolla Pharmaceutical Company | $102,103 | 0 |
| Angiotensin-II in Sepsis: Immune scRNA Seq Proposal Summary | La Jolla Pharmaceutical Company | $99,000 | 0 |
| EXPANDED ACCESS FOR LJPC-501 | La Jolla Pharmaceutical Company | $55,592 | 0 |
| EFFECT OF CARDIOPULMONARY BYPASS ON SERUM BIOMARKERS OF IRON | La Jolla Pharmaceutical Company | $16,296 | 0 |
| Angiotensin II as a first-line vasopressor for distributive shock for heart transplant and left ventricular assist device implantation recipients: A Pilot Study | La Jolla Pharmaceutical Company | $13,257 | 0 |
| The Effect of Angiotensin II on Vasoplegic Shock | La Jolla Pharmaceutical Company | $12,617 | 0 |
| Medication Use Evaluation with GIAPREZA for Patients with distributive shock including COVID-19 | La Jolla Pharmaceutical Company | $9,996 | 0 |
| Angiotensin II in Liver Transplantation (ANGLT-1): A Pilot Randomized Controlled Trial | La Jolla Pharmaceutical Company | $7,116 | 0 |
| DPP3, Angiotensin II, and Renin Kinetics in Sepsis (DARK-Sepsis) pilot: serum biomarkers to predict response to angiotensin II versus standard-of-care vasopressor therapy in the treatment of septic shock, a randomized controlled pilot trial | La Jolla Pharmaceutical Company | $1,920 | 0 |
Top Doctors Receiving Payments for GIAPREZA — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Surgical Critical Care | Los Angeles, CA | $22,466 | 24 |
| , MD | Internal Medicine | New York, NY | $21,814 | 17 |
| , MD | Surgery | Washington, DC | $19,140 | 21 |
| Mark Rumbak | — | Tampa, FL | $18,760 | 18 |
| , ACNP-BC | Critical Care Medicine | Livingston, NJ | $18,607 | 35 |
| , MD | Critical Care Medicine | Baltimore, MD | $17,815 | 20 |
| , M.D | Critical Care Medicine | Greensboro, NC | $16,933 | 23 |
| , MD | Critical Care Medicine | Fort Sam Houston, TX | $14,843 | 17 |
| , M.D | Pulmonary Disease | Georgetown, KY | $13,545 | 11 |
| , MD | Cardiovascular Disease | Pocatello, ID | $13,330 | 2 |
| , MD | Critical Care Medicine | Springfield, MA | $12,227 | 14 |
| , MD PHD | Cardiovascular Disease | Baltimore, MD | $12,000 | 6 |
| , MD | Pulmonary Disease | Durham, NC | $11,111 | 5 |
| , M.D | Internal Medicine | Houston, TX | $10,651 | 12 |
| , MD, PHD, MPH | Medical Toxicology | Sacramento, CA | $9,888 | 11 |
| , M.D | Pulmonary Disease | Aransas Pass, TX | $9,818 | 5 |
| , MD | Neurocritical Care | San Antonio, TX | $9,799 | 5 |
| , M.D | Nephrology | Lawrenceville, GA | $9,437 | 9 |
| , M.D | Pain Medicine | Westerville, OH | $8,799 | 2 |
| , M.D | Pulmonary Disease | Weston, FL | $8,755 | 7 |
| , M.D | Critical Care Medicine | Loma Linda, CA | $8,595 | 9 |
| , DO | Pediatrics | Charlotte, NC | $8,444 | 7 |
| Javier Perez Fernandez | Critical Care Medicine | South Miami, FL | $7,806 | 6 |
| , M.D | Critical Care Medicine | Rocky Mount, NC | $7,027 | 3 |
| , MD | Internal Medicine | Houston, TX | $6,968 | 3 |
Ad
Manufacturing Companies
- La Jolla Pharmaceutical Company $3.9M
- Mylan Inc. $15,952
Product Information
- Type Drug
- Total Payments $3.9M
- Total Doctors 6,320
- Transactions 11,921
About GIAPREZA
GIAPREZA is a drug associated with $3.9M in payments to 6,320 healthcare providers, recorded across 11,921 transactions in the CMS Open Payments database. The primary manufacturer is La Jolla Pharmaceutical Company.
Payment data is available from 2018 to 2024. In 2024, $349,779 was paid across 1,829 transactions to 1,398 doctors.
The most common payment nature for GIAPREZA is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.2M, 29.9% of total).
GIAPREZA is associated with 10 research studies, including "A Multi-Center, Randomized, Open-Label, Parallel Group Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Adult Patients With Transfusion-Dependent Beta Thalassemia" ($419,361).